Fig. 2: Pharmacologic inhibition of ABCC1 synergizes with BCL-2-inhibitors. | Nature Communications

Fig. 2: Pharmacologic inhibition of ABCC1 synergizes with BCL-2-inhibitors.

From: ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia

Fig. 2: Pharmacologic inhibition of ABCC1 synergizes with BCL-2-inhibitors.

A BLISS synergy score distribution of MOLM-13 cells treated with Venetoclax at indicated concentrations in combination with Reversan for 5 days, determined using SynergyFinder. Data are represented as the relative deviation from BLISS additivity. n = 2 experimental replicates. B Five-day dose–response curves of Venetoclax in MV4-11 (left) and HL-60 (right) cells, co-treated with either DMSO or 5 μM Reversan. Data are presented as mean values ± SD. n = 3 experimental replicates. C Structure of BH3-mimetics inhibiting the anti-apoptotic proteins BCL-2, BCL-xL and BCL-w. D Heatmap depicting the overall relative deviation from BLISS additivity (BLISS synergy score), determined by SynergyFinder of three different AML cell lines (MOLM-13, KG-1, PL-21) treated with Reversan or MK-571 with indicated drugs for five days. n = 2 experimental replicates. A, B, D Source data are provided as a Source Data file.

Back to article page